KR20100113542A - 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법 - Google Patents

보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법 Download PDF

Info

Publication number
KR20100113542A
KR20100113542A KR1020107017092A KR20107017092A KR20100113542A KR 20100113542 A KR20100113542 A KR 20100113542A KR 1020107017092 A KR1020107017092 A KR 1020107017092A KR 20107017092 A KR20107017092 A KR 20107017092A KR 20100113542 A KR20100113542 A KR 20100113542A
Authority
KR
South Korea
Prior art keywords
bosentane
bosentan
anhydrous
solvent
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107017092A
Other languages
English (en)
Korean (ko)
Inventor
다르마라즈 라마찬드라 라오
라젠드라 나라얀라오 칸칸
만진더 신그 풀
아쉬위니 아몰 사완트
Original Assignee
시플라 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시플라 리미티드 filed Critical 시플라 리미티드
Publication of KR20100113542A publication Critical patent/KR20100113542A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020107017092A 2008-01-01 2009-01-02 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법 Abandoned KR20100113542A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN12MU2008 2008-01-01
IN12/MUM/2008 2008-01-01
IN836MU2008 2008-04-09
IN836/MUM/2008 2008-04-09

Publications (1)

Publication Number Publication Date
KR20100113542A true KR20100113542A (ko) 2010-10-21

Family

ID=40424567

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107017092A Abandoned KR20100113542A (ko) 2008-01-01 2009-01-02 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법

Country Status (9)

Country Link
US (1) US8481730B2 (https=)
EP (2) EP2248805A3 (https=)
JP (1) JP5535082B2 (https=)
KR (1) KR20100113542A (https=)
AU (1) AU2009203174B2 (https=)
CA (1) CA2711043A1 (https=)
NZ (1) NZ586900A (https=)
WO (1) WO2009083739A1 (https=)
ZA (1) ZA201005014B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022546A1 (ko) * 2018-07-24 2020-01-30 주식회사 마더스제약 보센탄을 함유한 약학 제제

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
EP2248805A3 (en) 2008-01-01 2011-02-23 Cipla Ltd. Method of synthesis of bosentan, its polymorphic forms and its salts
CA2781541A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Crystalline forms of bosentan salt and processes for their preparation
JP5356323B2 (ja) * 2010-07-01 2013-12-04 富士化学工業株式会社 新規な非晶質ボセンタン及びその製造方法
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
ITMI20120701A1 (it) 2012-04-27 2013-10-28 Dipharma Francis Srl Procedimento per la purificazione di un composto benzensolfonammidico
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
EP2890694A4 (en) * 2012-08-31 2015-12-30 Rao Davuluri Ramamohan 4-TERT-BUTYL-N- [6- (2-HYDROXYETHOXY) -5- (2-METHOXYPHENOXY) -2 (2-PYRIMIDINYL) -PYRIMIDIN-4-YL) -BENZENESULFONAMIDE SODIUM
KR102004422B1 (ko) 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
US20250144095A1 (en) * 2022-02-03 2025-05-08 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
MXPA02007192A (es) 2000-01-25 2002-12-09 Hoffmann La Roche Preparacion de sulfonamidas.
CA2686457A1 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Novel polymorphic forms
US8664390B2 (en) * 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
NZ585438A (en) 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
EP2248805A3 (en) 2008-01-01 2011-02-23 Cipla Ltd. Method of synthesis of bosentan, its polymorphic forms and its salts
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022546A1 (ko) * 2018-07-24 2020-01-30 주식회사 마더스제약 보센탄을 함유한 약학 제제
KR20200011133A (ko) * 2018-07-24 2020-02-03 주식회사 마더스제약 보센탄을 함유한 약학 제제

Also Published As

Publication number Publication date
US20110015394A1 (en) 2011-01-20
US8481730B2 (en) 2013-07-09
AU2009203174A1 (en) 2009-07-09
EP2238118A1 (en) 2010-10-13
EP2248805A2 (en) 2010-11-10
WO2009083739A1 (en) 2009-07-09
NZ586900A (en) 2012-10-26
EP2248805A3 (en) 2011-02-23
JP5535082B2 (ja) 2014-07-02
JP2011508767A (ja) 2011-03-17
AU2009203174B2 (en) 2014-01-30
CA2711043A1 (en) 2009-07-09
ZA201005014B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
JP5535082B2 (ja) ボセンタン、その多形形態及びその塩の合成方法
JP6607780B2 (ja) Ｌｆａ−１阻害剤およびその多形
US9550735B2 (en) Process for the preparation of ivacaftor and solvates thereof
US20110312977A1 (en) Process for the preparation of voriconazole
JP5439168B2 (ja) ロスバスタチン亜鉛塩
US20110275687A1 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
EP4180423A1 (en) Novel tnf activity inhibitor compound, and pharmaceutically acceptable salt thereof
EP2882753A1 (en) Process for the preparation of pemetrexed and lysin salt thereof
JP2004520446A (ja) ロサルタンカリウムの結晶化方法
AU776696B2 (en) Process for preparing (1R,2S,4R) -(-)-2-((2'- (n,n-dimethylamino) -ethoxy)) -2-(phenyl) -1,7,7-tri- (methyl) -bicyclo (2.2.1) heptane and pharmaceutically acceptable acid addition salts thereof
KR102484846B1 (ko) 벤조피란 유도체의 정제방법, 이의 결정형 및 상기 결정형의 제조방법
WO2015104602A2 (en) A process for the preparation of anagliptin and its intermediates thereof
US20040138232A1 (en) Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity
US9505792B2 (en) Forms of cidofovir
JP7693921B2 (ja) プロリンアミド化合物の製造方法
CN121666381A (zh) 制备1-乙基-N-((1,2,3,5,6,7-六氢-s-二环戊二烯并苯-4-基)氨基甲酰基)哌啶-4-磺酰胺的制备方法
CN119859139A (zh) 双盐酸安罗替尼的固体形式及其制备方法
KR20250085607A (ko) 1-((3S,4R)-3-((2-((1-에틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의타타르산염, 이의 결정형 및 이의 제조 방법
EP1709034A2 (en) An improved process for the synthesis of losartan potassium
KR20140069378A (ko) 로수바스타틴 아연 염

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100730

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150619

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160330

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee